Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Genzyme Biosurgery (NasdaqNM:GZBX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Msgs | Insider | Options
Location
One Kendall Square
Cambride, MA 02139
Phone: (617) 252-7570
Fax: (617) 252-7600
Employees (last reported count): 4,400
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Products & Services
 ·Subsidiaries
 ·Divisions
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 30%
·Institutional: 33% (47% of float)
(105 institutions)
·Net Inst. Buying: 446.0K shares (+3.29%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Genzyme Biosurgery is the operating division of Genzyme Corporation that develops and markets instruments, devices, biomaterials and biotherapeutic products to improve or replace surgery, with an emphasis on orthopaedics and cardiothoracics markets. It is organized into three business units: Orthopaedics, Cardiothoracic and Biosurgical Specialties. Its product and development program portfolio consists of biomaterials, biotherapeutics, traditional devices and surgical closures, as well as advanced devices for minimally invasive cardiovascular surgery. Genzyme Biosurgery's sales force markets products directly to surgeons and hospital administrators throughout the United States and Europe. It also uses a network of distributors to sell products in Europe, Asia and Latin America.
More from Market Guide: Expanded Business Description

Financial Summary
GZBX is engaged in the manufacturer, development and marketing of biotechnology products that attempt to improve and/or replace surgery by growing tissues and organs in vitro for implantation to replace diseased or aged body parts. For the six months ended 6/30/01, revenues increased 61% to $114.5 million. Net loss totaled $72.9 million, up from $29.4 million. Revenues reflect growth in sales of Carticel chondrocytes. Net loss reflects increased R&D expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Henri Termeer, 55
Chairman, CEO
$1.9M
Earl Collier, Jr., 53
Pres
814K
Michael Wyzga, 46
CFO, Sr. VP
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GZBXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 6-Apr-2001
$3.95 
Recent Price$7.15 
52-Week High
on 19-Dec-2000
$11.75 
Daily Volume (3-month avg)107.2K
Daily Volume (10-day avg)76.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change-1.4%
26-Week Change
relative to S&P500
+7.4%
Share-Related Items
Market Capitalization$281.5M
Shares Outstanding39.4M
Float27.6M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$11.46 
Earnings (ttm)-$6.19 
Earnings (mrq)-$1.13 
Sales (ttm)$5.67 
Cash (mrq)$0.58 
Valuation Ratios
Price/Book (mrq)0.62 
Price/EarningsN/A 
Price/Sales (ttm)1.26 
Income Statements
Sales (ttm)$188.5M
EBITDA (ttm)-$163.6M
Income available to common (ttm)-$205.7M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-26.24%
Return on Equity (ttm)-42.84%
Financial Strength
Current Ratio (mrq)1.27 
Debt/Equity (mrq)0.51 
Total Cash (mrq)$23.0M
Short Interest
As of 8-Aug-2001
Shares Short680.0K
Percent of Float2.5%
Shares Short
(Prior Month)
869.0K
Short Ratio8.29 
Daily Volume82.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.